LGC has released ACCURUN^® SARS-CoV-2 Antigen Reference Material Kit, a new quality measurement tool to support SARS-CoV-2 antigen testing. It is formulated for use with test methods that detect the nucleocapsid (NP) protein of SARS-CoV-2 virus – the target for the majority of the SARS-CoV-2 antigen assays currently on the market.

The product comprises purified recombinant SARS-CoV-2 NP protein in simulated viral transport media. Offering both positive and negative materials, the kit is designed to support assay installation and monitoring of day-to-day assay performance, providing a complete quality solution for SARS-CoV-2 antigen testing.

Clinical laboratories are increasingly adopting antigen tests as a first line SARS-CoV-2 screening tool. While less accurate than amplification-based molecular tests, most antigen tests offer high specificity paired with a less complex, cost-effective design – making them more amendable to rapid, repeat testing of large populations in a point-of-care environment.

Bharathi Anekella, Executive Vice President and General Manager, LGC Clinical Diagnostics, stated, “We anticipate the demand for SARS-CoV-2 antigen testing to continue to be strong for the coming year, as it has become a preferred testing method for rapid large-scale screening, including back-to-work and back-to-school programs. Adding a quality solution like ACCURUN SARS-CoV-2 Antigen Reference Material Kit to the testing workflow offers a way to increase confidence in the results produced by these types of rapid diagnostics.”

To learn more about ACCURUN SARS-CoV-2 Antigen reference materials, as well as the complete line of SARS-CoV-2 Quality Solutions, please visit the LGC SeraCare website.

Learn more about ACCURUN^®

About LGC

LGC is a global leader in the life science tools sector, providing mission critical components to customers across clinical diagnostics, pharmaceutical, research & government, food and other applied markets.

LGC provides a comprehensive range of specialty genomic analysis tools, measurement tools and supply chain assurance solutions, underpinned by leading analytical and measurement science capabilities.  It holds a number of international roles, including the UK Government Chemist programme and serving as the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement.

LGC's scientific tools and solutions form an essential part of its customers' quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research. Its 4,000 employees include internationally-recognised scientists who are experts in their field. Headquartered in London, LGC operates out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.

LGC was founded in 1842. It has been privately-owned since 1996 and has diversified through internal investment and acquisitions to be an international leader in its chosen markets. LGC is now owned by funds affiliated to Cinven, Astorg and ADIA.

About LGC Clinical Diagnostics

LGC Clinical Diagnostics develops and manufactures a comprehensive portfolio of catalog and custom-developed diagnostic quality solutions and component materials for the extended life sciences industry. We partner with IVD assay developers, and pharmaceutical, CRO and academic institutions in commercialization activities across the entire diagnostic pipeline - from concept and early stage research, through expedited product development and onwards into routine clinical use. Laboratorians and diagnostic professionals across disciplines of clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics rely on LGC’s products to support accurate and reliable diagnostic results.

Our operating entities include SeraCare Life Sciences and Maine Standards Company, which are in vitro diagnostics (IVD) manufacturers of quality measurement tools (calibrators, controls, linearity, EQA/PT, biological materials) and the Native Antigen Company, which is a manufacturer and supplier of viral antigens. Our 300+ employees operate FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland, USA, and an ISO 9001-accredited facility in Oxford, UK.  

Each day, our world-class staff, scientific expertise, operational efficiency and superior quality systems are ready to support the range of advanced technologies that collectively improve patient outcomes - from the widely adopted and established through to cutting-edge NGS and precision diagnostics.